jeudi 24 mai 2018

Onco Actu du 24 mai 2018


1.4 Biologie - Technos

Single-cell approaches to immune profiling [Nature]

2.5 Etiologie - Gènes

Heredity beyond the gene [Nature]

2.7 Etiologie - Obésité

Diet, Nutrition, Physical Activity and Cancer: a Global Perspective [World Cancer Research Fund]

Cut out alcohol and bacon to slash cancer risk, say researchers [The Telegraph]

Obesity now linked to 12 different cancers [The Guardian]

4.12 Biopsies liquides

Freenome Sets Sights On Blood Test To Detect Colon Cancer [Forbes]

4.2 Dép., diag. & prono. - Génome

p53 and Me [NEJM]

4.9 Dép., diag. & prono. - Sein

The heterogeneity of cancer [Breast Cancer Research and Treatment]

5. Traitements

Some Children with Wilms Tumor Can Receive Less Therapy, Study Suggests [NCI]

How gut microbes are joining the fight against cancer [Nature]

5.12.4 Immunothérapies - Essais

Merck rains on Roche's parade with double Keytruda win in squamous lung cancer [FiercePharma]

Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival and Progression-Free Survival as First-Line Treatment for Squamous Non-Small Cell Lung Cancer (NSCLC) in Pivotal Phase 3 KEYNOTE-407 Tria [Merck]

Merck crushes Keynote-407 study in frontline lung cancer, hitting co-primaries and setting up another quick OK [EndPoints]

Merck's Keytruda succeeds in late-stage lung cancer study [Reuters]

5.2.1 Pharma - Partenariats

Amgen Enters Groundbreaking Collaboration To Improve Symptom Management During Cancer Treatment [Amgen]

5.2.3 Pharma - économie

Look out, J&J. Sun Pharma's Yonsa nod in prostate cancer puts Zytiga on notice [FiercePharma]

Sun Pharma Announces USFDA Approval of YONSA® (abiraterone acetate) To Treat Metastatic Castration-Resistant Prostate Cancer In Combination With Methylprednisolone [Sun Pharma]

5.4 Traitements - Economie

A focus on cost instead of value threatens the future of personalized medicine [STAT]

NICE Issues Technology Appraisal Guidance for Atezolizumab for Treating Locally Advanced or Metastatic NSCLC After Chemotherapy [ESMO]

5.5.1.1 ASCO (général) - Industriels

AstraZeneca heads to 2018 ASCO Annual Meeting with its diversified oncology portfolio and next-generation pipeline [AstraZeneca]

5.5.8 ASCO (poumon)

My Top 5 ASCO 2018 Abstracts in Stage I-III NSCLC, Small Cell Lung Cancer, & Mesothelioma [Jack West - YouTube]

6. Lutte contre les cancers

Scientists are declaring war against a leukemia-causing virus that has infected millions [Science]

6.1 Observation

Lung Cancer Incidence in Women under 50 Surpasses that in Men of the Same Age [ACS]

Lung cancer rates in younger white and Hispanic women surpass those of men [Washington Post]

6.10 Politiques

Framework for the UK-EU Partnership Science, Research and Innovation [GOV.UK]

6.10.1 Politiques (USA)

The American Association for Cancer Research Applauds Passage of the Childhood Cancer STAR Act [AACR]

6.5 Médecines alternatives

Death from Cancer Quackery – Black Salve Edition [Science-Based Medicine]

6.7 DMP, Big Data & applis

Should Tech Entrepreneurs Aspire to Fix Clinical Trials Or Reinvent Them? [Forbes]

Precision medicine paradox: Tech outpacing policy [Healthcare IT News]

6.7.1 IA/bioinformatique

Institut Curie names Intel lead partner to implement high performance computing and artificial intelligence in accelerating genome sequencing and interpretation for oncology [Institut Curie]

6.9 Controverses

J&J hit with $21.7 million verdict in another talc asbestos cancer case [Reuters]